Research ExplorerPublicationsNovoTTF-100A versus physician's choice chemotherapy in recur...

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Links

  • Roger Stupp
  • Eric T Wong
  • Andrew A Kanner
  • David Steinberg
  • Herbert Engelhard
  • Volkmar Heidecke
  • Eilon D Kirson
  • Sophie Taillibert
  • Frank Liebermann
  • Vladimir Dbalý
  • Zvi Ram
  • J Lee Villano
  • Nikolai Rainov
  • Uri Weinberg
  • David Schiff
  • Lara Kunschner
  • Jeffrey Raizer
  • Jerome Honnorat
  • Andrew Sloan
  • Mark Malkin
  • Joseph C Landolfi
  • Franz Payer
  • Maximilian Mehdorn
  • Robert J Weil
  • Susan C Pannullo
  • Manfred Westphal
  • Martin Smrcka
  • Lawrence Chin
  • Herwig Kostron
  • Silvia Hofer
  • Jeffrey Bruce
  • Rees Cosgrove
  • Nina Paleologous
  • Yoram Palti
  • Philip H Gutin

Related Research units

Abstract

NovoTTF-100A is a portable device delivering low-intensity, intermediate frequency electric fields via non-invasive, transducer arrays. Tumour Treatment Fields (TTF), a completely new therapeutic modality in cancer treatment, physically interfere with cell division.

Bibliographical data

Original languageEnglish
Article number14
ISSN0959-8049
Publication statusPublished - 2012
pubmed 22608262